These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 27816320)

  • 1. Comparison of mid-term clinical outcomes between "complete full-metal jacket strategy" versus "incomplete full-metal jacket strategy" for diffuse right coronary artery stenosis with drug-eluting stents.
    Yamamoto K; Sakakura K; Adachi Y; Taniguchi Y; Wada H; Momomura SI; Fujita H
    J Cardiol; 2017 Jun; 69(6):823-829. PubMed ID: 27816320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended follow-up following "full-metal jacket" percutaneous coronary interventions with drug-eluting stents.
    Basavarajaiah S; Naganuma T; Latib A; Hasegawa T; Sharp A; Rezq A; Sticchi A; Figini F; Amato A; Colombo A
    Catheter Cardiovasc Interv; 2014 Dec; 84(7):1042-50. PubMed ID: 24550090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Percutaneous coronary intervention using a full metal jacket with drug-eluting stents: major adverse cardiac events at one year.
    Calé R; Teles RC; Almeida M; Rosário Id; Sousa PJ; Brito J; Raposo L; Gonçalves Pde A; Gabriel HM; Mendes M
    Arq Bras Cardiol; 2013 Aug; 101(2):117-26. PubMed ID: 23821408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long term follow-up of "full metal jacket" of de novo coronary lesions with new generation Zotarolimus-eluting stents.
    Durante A; Foglia Manzillo G; Burzotta F; Trani C; Aurigemma C; Summaria F; Patrizi R; Talarico GP; Latib A; Figini F; Romagnoli E; De Vita M; Fantoni C; My L; Larosa C; Manzoli A; Turturo M; Berni A; Corrado G
    Int J Cardiol; 2016 Oct; 221():1008-12. PubMed ID: 27441483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term clinical outcomes after percutaneous coronary intervention for ostial/mid-shaft lesions versus distal bifurcation lesions in unprotected left main coronary artery: the DELTA Registry (drug-eluting stent for left main coronary artery disease): a multicenter registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment.
    Naganuma T; Chieffo A; Meliga E; Capodanno D; Park SJ; Onuma Y; Valgimigli M; Jegere S; Makkar RR; Palacios IF; Costopoulos C; Kim YH; Buszman PP; Chakravarty T; Sheiban I; Mehran R; Naber C; Margey R; Agnihotri A; Marra S; Capranzano P; Leon MB; Moses JW; Fajadet J; Lefevre T; Morice MC; Erglis A; Tamburino C; Alfieri O; Serruys PW; Colombo A
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1242-9. PubMed ID: 24355114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Full Metal Jacket With Drug-Eluting Stents for Coronary Chronic Total Occlusion.
    Lee PH; Lee SW; Yun SC; Bae J; Ahn JM; Park DW; Kang SJ; Kim YH; Lee CW; Park SW; Park SJ
    JACC Cardiovasc Interv; 2017 Jul; 10(14):1405-1412. PubMed ID: 28668311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term (8 year) outcomes and predictors of major adverse cardiac events after full metal jacket drug-eluting stent implantation.
    Lee CW; Ahn JM; Lee JY; Kim WJ; Park DW; Kang SJ; Lee SW; Kim YH; Park SW; Park SJ;
    Catheter Cardiovasc Interv; 2014 Sep; 84(3):361-5. PubMed ID: 24150889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Full-metal jacket technique using second-generation drug-eluting stent: clinical and angiographic follow-up in 2 years.
    Yoshioka G; Kuriyama N; Watanabe N; Ashikaga K; Shibata Y; Node K
    Cardiovasc Interv Ther; 2019 Oct; 34(4):305-311. PubMed ID: 30767111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: 5 years follow-up from the randomized DEDICATION trial (Drug Elution and Distal Protection in Acute Myocardial Infarction).
    Holmvang L; Kelbæk H; Kaltoft A; Thuesen L; Lassen JF; Clemmensen P; Kløvgaard L; Engstrøm T; Bøtker HE; Saunamäki K; Krusell LR; Jørgensen E; Tilsted HH; Christiansen EH; Ravkilde J; Køber L; Kofoed KF; Terkelsen CJ; Helqvist S
    JACC Cardiovasc Interv; 2013 Jun; 6(6):548-53. PubMed ID: 23683734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials.
    Claessen BE; Smits PC; Kereiakes DJ; Parise H; Fahy M; Kedhi E; Serruys PW; Lansky AJ; Cristea E; Sudhir K; Sood P; Simonton CA; Stone GW
    JACC Cardiovasc Interv; 2011 Nov; 4(11):1209-15. PubMed ID: 22115661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of coronary anatomy and stenting technique on long-term outcome after drug-eluting stent implantation for unprotected left main coronary artery disease.
    Tiroch K; Mehilli J; Byrne RA; Schulz S; Massberg S; Laugwitz KL; Vorpahl M; Seyfarth M; Kastrati A;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):29-36. PubMed ID: 24332416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effects of drug-eluting stents versus bare metal stents on patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: outcomes of 3-year clinical follow-up.
    Wang CH; Fang Q; Zhang SY; Shen ZJ; Fan ZJ; Jin XF; Zeng Y; Liu ZY; Xie HZ; Yang M
    Chin Med J (Engl); 2012 Aug; 125(16):2803-6. PubMed ID: 22932070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
    Gada H; Kirtane AJ; Newman W; Sanz M; Hermiller JB; Mahaffey KW; Cutlip DE; Sudhir K; Hou L; Koo K; Stone GW
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1263-6. PubMed ID: 24239202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of drug-eluting balloons alone or in combination with drug-eluting stents in the treatment of de novo diffuse coronary disease.
    Costopoulos C; Latib A; Naganuma T; Sticchi A; Figini F; Basavarajaiah S; Carlino M; Chieffo A; Montorfano M; Naim C; Kawaguchi M; Giannini F; Colombo A
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1153-9. PubMed ID: 24262615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
    Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of early- and new-generation drug-eluting stent implantations for ostial right coronary artery lesions.
    Watanabe Y; Takagi K; Naganuma T; Nakamura S
    Cardiovasc Ther; 2017 Apr; 35(2):. PubMed ID: 28039928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Five-year long-term clinical follow-up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT FIRST trial.
    Wiemer M; Serruys PW; Miquel-Hebert K; Neumann FJ; Piek JJ; Grube E; Haase J; Thuesen L; Hamm C
    Catheter Cardiovasc Interv; 2010 Jun; 75(7):997-1003. PubMed ID: 20517959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and effectiveness of drug-eluting stents versus bare-metal stents in elderly patients with small coronary vessel disease.
    Puymirat E; Mangiacapra F; Peace A; Ntarladimas Y; Conte M; Bartunek J; Vanderheyden M; Wijns W; de Bruyne B; Barbato E
    Arch Cardiovasc Dis; 2013 Nov; 106(11):554-61. PubMed ID: 24231052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two-year outcomes after treatment of severely calcified coronary lesions with the orbital atherectomy system and the impact of stent types: Insight from the ORBIT II trial.
    Généreux P; Bettinger N; Redfors B; Lee AC; Kim CY; Lee MS; Shlofmitz RA; Moses JW; Stone GW; Chambers JW
    Catheter Cardiovasc Interv; 2016 Sep; 88(3):369-77. PubMed ID: 27084293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Everolimus-eluting stents versus sirolimus- or paclitaxel-eluting stents: two-year results from the Guthrie Health Off-Label Stent (GHOST) registry.
    Harjai KJ; Kondareddy S; Pinkosky B; Harjai N; Orshaw P; Boura J
    J Interv Cardiol; 2013 Apr; 26(2):153-62. PubMed ID: 23363439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.